Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769560 · ClinicalTrials.gov registry record · NA
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
A NA study of Human Papillomavirus-Related Carcinoma, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 661
- Enrollment target
- 1
- Study location
NCT01769560: Completed NA study of Human Papillomavirus-Related Carcinoma, sponsored by University of Michigan.
NCT01769560 is a NA study of Human Papillomavirus-Related Carcinoma that has completed, run by University of Michigan. The registered enrollment target is 661 participants, above the 313-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (111% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769560, a NA study of Human Papillomavirus-Related Carcinoma, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 661 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
Primary Outcome
Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, "I have received at least 1 dose of the HPV vaccine" at 3 and 12 months.
Conditions Studied
Interventions
- BEHAVIORAL MeFirst Tailored Intervention
Study Locations (1)
Michigan
- Univeristy of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT01769560 record still lists
NCT01769560 is an interventional study that assigns participants to a tested intervention. The registered 661 participants enrollment target is mid-sized for trials with a published cap, above the 313-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (111% higher).
The record links to 1 condition, with Human Papillomavirus-Related Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which MeFirst Tailored Intervention is the first listed.
NCT01769560 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01769560 about?
NCT01769560 is a clinical study titled "MeFirst: A Tailored Intervention to HPV Vaccine Decision Making". This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
What is the current status of trial NCT01769560?
This trial is currently completed. It is a NA study. The enrollment target is 661 participants. The study started on 2013-01. Estimated completion is 2014-04.
What conditions does trial NCT01769560 study?
This clinical trial studies the following conditions: Human Papillomavirus-Related Carcinoma.
What interventions are being tested in trial NCT01769560?
The interventions under investigation include: MeFirst Tailored Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01769560?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769560 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
RECRUITING · NA
-
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
RECRUITING · Phase 1
-
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
ACTIVE NOT RECRUITING · Phase 1
-
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
ACTIVE NOT RECRUITING · Phase 2
-
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia